Publications Metastatic Breast Cancer

  • « overview publications


  • Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment - the TBP phase III study (GBG 26/BIG3-05). G.

    von Minckwitz, C. Zielinski, E. Maarteense, P. Vogel, M. Schmidt, H. Eidtmann, T. Cufer, F. E. de Jongh, M. Kaufmann, S. Loibl

    J. Clin. Oncol. 26:2008 (May 20 suppl; abstr. 1025)

  • Concomitant Docetaxel plus Gemcitabine (DG) vs. Sequential Docetaxel followed by Gemcitabine (D->) in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients: A Multicenter Phase III Trial of the Central European Cooperative Oncology Group (CECOG).

    A. Tomova, T. Brodowicz, V. Tzekova, C. Timcheva, C. Wiltschke, D. Abi Gerges, J. Pawlega, S. Spanik, M. Inbar, C. Zielinski

    J. Clin. Oncol (Supplement to 26) 2008: # 1106

  • The manuscript "Gemcitabine, Epirubicin and Paclitaxel Versus Fluorouracil, Epirubicin and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial" has been published in the Journal of Clinical Oncology, volume 23, number 7, issue March 1st, 2005.

    Download Journal of Clinical Oncology - Original Report (pdf - 169kb)

  • Gemcitabine, Epirubicin and Paclitaxel (GET) vs. 5-Fluorouracil,  Epirubicin and Cyclophosphamide (FEC) as First-Line Treatment  in Metastatic Breast Cancer (MBC): Demographics of a Randomised, Multicenter Phae III Trial of the  Central European Cooperative Oncology (CECOG).

    C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic, J. Jassem, C. Wiltschke, Z. Kahan, M. Grgic, V. Tzekova, M. Inbar, T. Brodowicz.

    ASCO 2003

  • Gemcitabine, Epirubicin and Paclitaxel (GET) vs. 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) as First-Line Treatment in Metastatic Breast Cancer: Interim Toxicity Analysis of a Randomised, Multicenter Phase III Trial of the Central European Cooperative Oncology Group (CECOG).

    C. Zielinski, S. Beslija, J. Cervek, Z. Mrsic-Krmpotic, I. Tchernozemsky, C. Wiltschke, N. Ghilezan, M. Grgic, J. Jassem, V. Tzekova, Z. Kahan, J. Pawlega, H. Onat, M. Inbar, and T. Brodowicz for the Central European Cooperative Oncology Group.

    ASCO, 2001

  • Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase III trial of the Central European Cooperative Oncology Group (CECOG).

    T. Brodowicz, S. Beslija, J. Cervek, Z. Mrsic-Krmpotic, I. Tchernozemsky, C. Wiltschke, N. Ghilezan, M. Grgic, J. Jassem, C. Zielinski for the Central European Cooperative Oncology Group.

    ECCO 2001





For publications of the results of the Consensus Conferenences
see Consensus Statements